M3, Inc. (MTHRY)
OTCMKTS
· Delayed Price · Currency is USD
6.13
-0.24 (-3.69%)
Apr 29, 2025, 11:03 AM EDT
M3, Inc. Revenue
M3, Inc. had revenue of 80.70B JPY in the quarter ending December 31, 2024, with 27.30% growth. This brings the company's revenue in the last twelve months to 265.22B, up 12.93% year-over-year. In the fiscal year ending March 31, 2024, M3, Inc. had annual revenue of 238.88B with 3.49% growth.
Revenue (ttm)
265.22B JPY
Revenue Growth
+12.93%
P/S Ratio
5.01
Revenue / Employee
21.92M JPY
Employees
12,100
Market Cap
8.45B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 238.88B | 8.07B | 3.49% |
| Mar 31, 2023 | 230.82B | 22.66B | 10.89% |
| Mar 31, 2022 | 208.16B | 38.96B | 23.03% |
| Mar 31, 2021 | 169.20B | 38.23B | 29.19% |
| Mar 31, 2020 | 130.97B | 17.91B | 15.84% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |
M3, Inc. News
- 4 years ago - M3, Inc.: Stand-Out Success Story Of Japanese Internet - Seeking Alpha
- 4 years ago - 5 Health Care Stocks Growing Fast - GuruFocus
- 4 years ago - 5 Telehealth Stocks for Long-Term Financial Fitness - Kiplinger